Purpose The role of temporary ovarian suppression with gonadotropin-releasing hormone
agonists (GnRHa) during chemotherapy as a strategy to preserve ovarian function and …

PURPOSE Many patients and physicians remain concerned about the potential detrimental
effects of pregnancy after breast cancer (BC) in terms of reproductive outcomes and …

Background Prospective data on the risk of recurrence among women with hormone
receptor–positive early breast cancer who temporarily discontinue endocrine therapy to …

Highlights•Breast cancer in young women should be treated based on stage and biology of
disease.•Management of breast cancer in young women requires special considerations …

Background Ovarian failure is a common toxic effect of chemotherapy. Studies of the use of
gonadotropin-releasing hormone (GnRH) agonists to protect ovarian function have shown …

Importance Young women with breast cancer who have germline pathogenic variants
inBRCA1orBRCA2face unique challenges regarding fertility. Previous studies …

In the United States, one in 196 women is diagnosed with breast cancer under the age of 40
years. Adolescents and young adults (AYAs), of age 15-39 years at diagnosis, experience a …

Breast cancer is the most common cancer of adolescents and young adult (AYA) women
aged 15 to 39 years, accounting for 5.6% of all invasive breast cancer in women. In …

In the last years, thanks to the improvement in the prognosis of cancer patients, a growing
attention has been given to the fertility issues. International guidelines on fertility …

Background The role of temporary ovarian suppression with luteinizing hormone-releasing
hormone agonists (LHRHa) in the prevention of chemotherapy-induced premature ovarian …